Compare ATR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATR | PRAX |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.1B |
| IPO Year | 1995 | 2020 |
| Metric | ATR | PRAX |
|---|---|---|
| Price | $129.08 | $323.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $170.25 | ★ $572.13 |
| AVG Volume (30 Days) | 393.1K | ★ 514.9K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ 6.51 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $3,777,181,000.00 | N/A |
| Revenue This Year | $5.18 | N/A |
| Revenue Next Year | $4.98 | $7,758.26 |
| P/E Ratio | $115.43 | ★ N/A |
| Revenue Growth | ★ 5.42 | N/A |
| 52 Week Low | $103.23 | $37.25 |
| 52 Week High | $164.28 | $366.52 |
| Indicator | ATR | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 68.00 | 50.02 |
| Support Level | $121.60 | $307.93 |
| Resistance Level | $132.42 | $327.65 |
| Average True Range (ATR) | 2.31 | 19.92 |
| MACD | 0.31 | -0.36 |
| Stochastic Oscillator | 90.36 | 15.05 |
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.